Marker Therapeutics Inc

Marker Therapeutics Inc Stock Forecast & Price Prediction

Live Marker Therapeutics Inc Stock (MRKR) Price
$2.77

0

Ratings

  • Buy 0
  • Hold 0
  • Sell 0
Disclaimer : Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance. This information is for educational purposes only and should not be construed as advice to buy or sell any security.

Stock Price

$2.77

P/E Ratio

-3.72

Volume Traded Today

$15,700

Dividend

Dividends not available for MRKR

52 Week High/low

6.80/2.40

Marker Therapeutics Inc Market Cap

$32.3M

๐Ÿ›‘ Alert: These ten stocks could have higher potential than $MRKR ๐Ÿ›‘

Before you buy MRKR you'll want to see this list of ten stocks that have huge potential. Want to see if MRKR made the cut? Enter your email below

MRKR Summary

From what 0 stock analysts predict, the share price for Marker Therapeutics Inc (MRKR) might increase by 324.19% in the next year. This is based on a 12-month average estimation for MRKR. Price targets go from $11 to $12.5. The majority of stock analysts believe MRKR is a sell. Please note analyst price targets are not guaranteed and could be missed completely.

MRKR Analyst Ratings

About 0 Wall Street analysts have assigned MRKR 0 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Marker Therapeutics Inc to perform worse than the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on MRKR. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.

MRKR stock forecast by analyst

These are the latest 20 analyst ratings of MRKR.

Analyst/Firm

Rating

Price Target

Change

Date

Aydin Huseynov
Ladenburg Thalmann

Buy

$11

Initiates

Apr 30, 2024
Tony Butler
Roth Capital

Neutral

$1

Downgrade

Feb 17, 2022

Piper Sandler

Overweight


Initiates

Mar 25, 2021

Cantor Fitzgerald

Overweight


Initiates

Mar 19, 2021

Cantor Fitzgerald

Overweight


Initiates

Mar 18, 2021
Edward Tenthoff
Piper Sandler

Neutral

$2.5

Downgrade

May 12, 2020

Piper Jaffray

Overweight


Maintains

Nov 13, 2019

Janney Montgomery Scott

Buy

$10

Maintains

Nov 13, 2019

Piper Sandler

Overweight

$6

Maintains

Nov 13, 2019

Janney Capital

Buy


Maintains

Nov 13, 2019

Oppenheimer

Outperform


Initiates

Jul 3, 2019

Roth Capital

Buy


Initiates

May 30, 2019

WBB Securities

Strong Buy


Upgrade

Mar 29, 2019

Janney Montgomery Scott

Buy


Initiates

Mar 1, 2019

Janney Capital

Buy


Initiates

Mar 1, 2019

MRKR Company Information

  • Company Type: Clinical-stage immuno-oncology company
  • Focus: Development and commercialization of novel T cell-based immunotherapies
  • Treatment Areas: Hematological malignancies and solid tumor indications
  • Key Technology: Multi tumor-associated antigen-specific T cell technology
  • Products in Development:
    • MT-401-OTS: Targeting acute myeloid leukemia
    • MT-601: Targeting lymphoma and pancreatic cancer
  • Headquarters: Houston, Texas
MRKR
Marker Therapeutics Inc (MRKR)

When did it IPO

N/A

Staff Count

8

Country

United States

Sector/Industry

Healthcare/Biotechnology

CEO

Dr. Juan F. Vera M.D.

Market Cap

$32.3M

Marker Therapeutics Inc (MRKR) Financial Data

In 2023, MRKR generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that MRKR's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.

Revenue From 2020

$466,785

Revenue From 2021

$0

-100.00 %
From Previous Year

Revenue From 2022

$0

0.00 %
From Previous Year

Revenue From 2023

$0

0.00 %
From Previous Year
  • Revenue TTM $3.7M
  • Operating Margin TTM -197.4%
  • Gross profit TTM $0
  • Return on assets TTM -40.9%
  • Return on equity TTM -71.7%
  • Profit Margin -278.2%
  • Book Value Per Share 1.09%
  • Market capitalisation $32.3M
  • Revenue for 2021 $0
  • Revenue for 2022 $0
  • Revenue for 2023 $0
  • EPS this year (TTM) $-1.15

Marker Therapeutics Inc (MRKR) Latest News

No news data available.

...

MRKR Frequently asked questions

The highest forecasted price for MRKR is $12.5 from at .

The lowest forecasted price for MRKR is $11 from Aydin Huseynov from Ladenburg Thalmann

The MRKR analyst ratings consensus are 0 buy ratings, 0 hold ratings, and 0 sell ratings.